• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Repligen enrolls first patient in phase I trial of Friedreich’s Ataxia

Repligen enrolls first patient in phase I trial of Friedreich’s Ataxia

March 19, 2012
CenterWatch Staff

Waltham, Mass.-based Repligen has enrolled the first patient in a phase I clinical trial of RG2833 in adult patients with Friedreich’s Ataxia (FA)—a debilitating, life-shortening, degenerative neuro-muscular disorder that currently has no treatment.

Repligen’s RG2833 is a class 1 Histone Deacetylase (HDAC) inhibitor specifically designed to increase frataxin protein production in FA patients, targeting the genetic mutation that is the fundamental cause of the disease. The potential for HDAC inhibitors as a therapy for FA was first demonstrated by Dr. Joel Gottesfeld and his colleagues at Scripps Research Institute in La Jolla, Calif., whom Repligen has worked with to optimize and develop their own HDAC inhibitors and prepare them for human clinical trials.

"Friedreich's Ataxia disease biology provides evidence that a small increase in expression of the defective gene could potentially slow disease progression," said James R. Rusche, Ph.D., senior vice president, R&D, Repligen. "RG2833 is the first compound that targets activation of this defective gene. If our unique approach of using small molecules for protein replacement is successful, it has the potential to significantly improve outcomes for patients with FA.”

Rusche added, “We are hopeful that the phase I trial will elucidate the role for HDAC inhibition in FA, and inform future efficacy studies."

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing